Evidence map›Paper›PMID 31906958›Full record

ArticleBMC medical genomics2020

MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip.

Li Gao, Shi-Bai Yan, Jie Yang, Jin-Liang Kong, Ke Shi, Fu-Chao Ma, Lin-Zhen Huang, Jie Luo, Shu-Ya Yin, Rong-Quan He and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Li GaoDepartment of Pathology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Shi-Bai YanDepartment of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Jie YangDepartment of Pharmacology, School of Pharmacy, Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Jin-Liang KongDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Ke ShiDepartment of Pathology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Fu-Chao MaDepartment of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Lin-Zhen HuangDepartment of Pathology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Jie LuoDepartment of Medical Oncology, the Second Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Shu-Ya YinDepartment of Pathology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Rong-Quan HeDepartment of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
Xiao-Hua HuDepartment of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China. huxiaohua@gxmu.edu.cn.
Gang ChenDepartment of Pathology, the First Affiliated Hospital of Guangxi Medical University, Zhuang Autonomous Region, Nanning, 530021, Guangxi, China. chengang@gxmu.edu.cn.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMiR-182-5p, a cancer-related microRNA (miRNA), modulates tumorigenesis and patient outcomes in various human malignances. This study interroted the clinicopathological significance and molecular mechanisms of miR-182-5p in non-small cell lung cancer (NSCLC).

methodsThe clinical significance of miR-182-5p in NSCLC subtypes was determined based on an analysis of 124 samples (lung adenocarcinomas [LUADs], n = 101; lung squamous cell carcinomas [LUSCs], n = 23) obtained from NSCLC patients and paired noncancer tissues and an analysis of data obtained from public miRNA-seq database, miRNA-chip database, and the scientific literature. The NSCLC samples (n = 124) were analyzed using the real-time quantitative polymerase chain reaction (RT-qPCR). Potential targets of miR-182-5p were identified using lists generated by miRWalk v.2.0, a comprehensive atlas of predicted and validated targets of miRNA-target interactions. Molecular events of miR-182-5p in NSCLC were unveiled based on a functional analysis of candidate targets. The association of miR-182-5p with one of the candidate target genes, homeobox A9 (HOXA9), was validated using in-house RT-qPCR and dual-luciferase reporter assays.

resultsThe results of the in-house RT-qPCR assays analysis of data obtained from public miRNA-seq databases, miRNA-chip databases, and the scientific literature all supported upregulation of the expression level of miR-182-5p level in NSCLC. Moreover, the in-house RT-qPCR data supported the influence of upregulated miR-182-5p on malignant progression of NSCLC. In total, 774 prospective targets of miR-182-5p were identified. These targets were mainly clustered in pathways associated with biological processes, such as axonogenesis, axonal development, and Ras protein signal transduction, as well as pathways involved in axonal guidance, melanogenesis, and longevity regulation, in multiple species. Correlation analysis of the in-house RT-qPCR data and dual-luciferase reporter assays confirmed that HOXA9 was a direct target of miR-182-5p in NSCLC.

conclusionsThe miR-182-5p expression level was upregulated in NSCLC tissues. MiR-182-5p may exert oncogenic influence on NSCLC through regulating target genes such as HOXA9.

Indexed as

Carcinoma, Non-Small-Cell LungHomeodomain ProteinsLung NeoplasmsMicroRNAsNeoplasm ProteinsRNA, NeoplasmAgedComputer SimulationFemaleHumansMaleMiddle AgedOligonucleotide Array Sequence AnalysisReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA-Seqhomeobox protein HOXA9Homeodomain ProteinsMicroRNAsMirn182 microRNA, humanNeoplasm ProteinsRNA, NeoplasmHOXA9miR-182-5pmiRNA-chipsmiRNA-seqNon-small cell lung cancerRT-qPCR

Identifiers

PMID31906958
PMCPMC6945423
OpenAlexW3006477432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.